Mo-99 supply put at risk by COVID-19 pandemic

April 7, 2020, 10:18AMNuclear News

The U.S. healthcare industry is warning that the COVID-19 pandemic may threaten supplies of the medical radioisotope molybdenum-99, whose decay product, technetium-99m, is considered the workhorse isotope in nuclear medicine for diagnostic imaging. The online magazine Radiology Business recently reported that the American Society of Nuclear Cardiology (ASNC) alerted its members on April 1 that it is monitoring supply shortages of Mo-99 “more closely than ever” during the pandemic.

To continue reading, log in or create a free account!

Related Articles

Washington legislators look to nuclear

February 26, 2026, 7:19AMNuclear News

It has been an unusually busy week in the world of West Coast nuclear legislative momentum. In California, a bill is aiming to effectively repeal the state’s nuclear moratorium, while in...

ANSTO-designed target increases Mo-99 yield

February 25, 2026, 1:00PMNuclear News

The Australian Nuclear Science and Technology Organization (ANSTO) announced that it has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99, with less...